Loren Data's SAM Daily™

fbodaily.com
Home Today's SAM Search Archives Numbered Notes CBD Archives Subscribe
FBO DAILY ISSUE OF SEPTEMBER 07, 2008 FBO #2477
SOLICITATION NOTICE

66 -- Illumina Solexa Genome Analyzer Reagents, Expression Beadchips, Genotyping and Methylation Array Kits

Notice Date
9/5/2008
 
Notice Type
Presolicitation
 
NAICS
325413 — In-Vitro Diagnostic Substance Manufacturing
 
Contracting Office
Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
 
ZIP Code
20852
 
Solicitation Number
NCI-80227-MM
 
Archive Date
10/7/2008
 
Point of Contact
Melissa P Marino,, Phone: 301-402-4509, Caren N Rasmussen,, Phone: (301) 402-4509
 
E-Mail Address
marinome@mail.nih.gov, cr214i@nih.gov
 
Small Business Set-Aside
N/A
 
Description
<!--[if gte mso 9]><xml> <w:WordDocument> <w:View>Normal</w:View> <w:Zoom>0</w:Zoom> <w:PunctuationKerning /> <w:ValidateAgainstSchemas /> <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid> <w:IgnoreMixedContent>false</w:IgnoreMixedContent> <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText> <w:Compatibility> <w:BreakWrappedTables /> <w:SnapToGridInCell /> <w:WrapTextWithPunct /> <w:UseAsianBreakRules /> <w:DontGrowAutofit /> </w:Compatibility> <w:BrowserLevel>MicrosoftInternetExplorer4</w:BrowserLevel> </w:WordDocument> </xml><![endif]--><!--[if gte mso 9]><xml> <w:LatentStyles DefLockedState="false" LatentStyleCount="156"> </w:LatentStyles> </xml><![endif]--> <!--[if gte mso 10]> <style> /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-parent:""; mso-padding-alt:0in 5.4pt 0in 5.4pt; mso-para-margin:0in; mso-para-margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:10.0pt; font-family:"Times New Roman"; mso-ansi-language:#0400; mso-fareast-language:#0400; mso-bidi-language:#0400;} </style> <![endif]--> The National Cancer Institute (NCI), Genetics Branch plans to procure on a sole source basis, Illumina Solexa Genome Analyzer Reagents, Expression Beadchips, Genotyping and Methylation Array Kits with Illumina, Inc; 9885 Towne Center Drive; San Diego, California 92121. The supplies are herein are being procured in accordance with the simplified acquisition procedures authorized by FAR Part 13.106-(b) (1). The North American Industry Classification System Code is 325413 and the business size standard is 500 employees. The Genetics Branch of the Center for Cancer Research at the National Cancer Institute is engaged in investigating genetic alteration and its effect on the development and biology of cancer. Through using ultra-high throughput, next generation sequencing, and whole-genome high-resolution beadchip reagents, the study DNA/promoter interactions, gene expression, methylation status, single nucleotide polymorphism (SNP), and investigate genomic rearrangements and the Illumina Genome Analyzer or BeadArray Reader have reached resolutions and informatic levels never before possible. The government owned Illumina Genome Analyzer is a massive parallel next-generation sequencing by synthesis instrument, which has become a core technology for genome analysis and discovery in our laboratory as is related to the biology of cancer. High throughput sequencing is a highly competitive and rapidly evolving technology where the ability to generate every increasing amounts of sequence data is key. The reagents allow the ability to continue to generate sequence date relevant to research on the Illumina Genome Analyzer. The Illumina Mouse and Human Ref8 expression beadchips are a unique approach to addressing reproducibility and quality issues in microarray data. Each beadtype or target is present as 30-40 replicate beads. By hybridizing to replicate targets, the average data will provide reproducibility and quality never before possible. Further, due to the high density of the micro-beads, multiple arrays (8) are manufactured on a single slide allowing multiple consecutive experiments to be performed. Illumina Solexa Genome Analyzer Reagents, Expression Beadchips, Genotyping and Methylation Array Kits are necessary to: <!--[if !supportLists]--> 1. <!--[endif]--> The Illumina Expression Beadchips, Genotyping and Methylation Array Kits are targets, which are present on the array at a 30-fold redundancy and allow inlier and outlier statistical analysis of common beadtype data pools. <!--[if !supportLists]--> 2. <!--[endif]--> The Illumina Expression Beadchips, Genotyping and Methylation Array Kits are feature target elements 3 microns in size as is appropriate to the 0.8 micron scanning system. <!--[if !supportLists]--> 3. <!--[endif]--> The Human Methylation27 beadchip allows interrogation of the methylation status of approximately 24,000 cpG loci simultaneously in a single assay. <!--[if !supportLists]--> 4. <!--[endif]--> The Illumina Paired End GAII reagents allow 3.0GB paired end reads with a single-read runtime of 2.5 days with <1.5% error at base 35. Illumina Solexa Genome Analyzer Reagents, Expression Beadchips, Genotyping and Methylation Array Kits are specifically designed for the existing Illumina Genome Analyzer and Illumina BeadArray Reader currently in the lab at NIH. Illumina is the sole source of the Genome Analyzer and BeadArray Reader and is the sole source for reagents appropriate for use on the instrumentation. The reagent content related to the Genome Analyzer and BeadArray Reader is proprietary and protected under patent rights and thereby is unavailable from other sources than the original manufacturer. Use of any other source reagents on these instruments would void support of the assays by Illumina. For these reasons, Illumina is the only source known to the NCI capable of performing the work outlined in the procurement. This is not a request for competitive quotation. However, if any interested party believes it can meet the above requirement, it may submit a statement of capabilities. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow the researcher to determine if the party can meet this requirement. One (1) original and one (1) copy of the capability statement must be received in the contracting office by 1:00 p.m. ET on September 22, 2008. All questions must be in writing and can be faxed to 301-402-4513 or sent via email to Melissa Marino: marinome@mail.nih.gov. It is the vendor’s responsibility to ensure questions have been received. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. In order to receive an award, contractor must have valid, updated registration and certification in the Central Contractor Registration (CCR) and the Online Representations and Certifications Application (ORCA). Please reference NCI-80227-MM on all correspondence.
 
Web Link
FedBizOpps Complete View
(https://www.fbo.gov/?s=opportunity&mode=form&id=5ab98f7cd325c7b806e03aab28cb566e&tab=core&_cview=1)
 
Record
SN01661651-W 20080907/080905223240-5ab98f7cd325c7b806e03aab28cb566e (fbodaily.com)
 
Source
FedBizOpps Link to This Notice
(may not be valid after Archive Date)

FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |
ECGrid: EDI VAN Interconnect ECGridOS: EDI Web Services Interconnect API Government Data Publications CBDDisk Subscribers
 Privacy Policy  © 1994-2020, Loren Data Corp.